| Total | ULBP3 |  |  | ULBP4 |  |  | ULBP5 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  |  | Low |  | High |  | Low |  | High |  | Low |  | High |  |
 | N | % | N | % | N | % | N | % | N | % | N | % | N | % |
Age | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
< 40 40-50 50-60 > = 60 | 48 145 132 249 | 8.4 25.3 23.0 43.4 | 25 84 68 128 | 8.2 27.5 22.3 42.0 | 11 24 22 55 | 9.8 21.4 19.6 49.1 | 29 91 86 164 | 7.8 24.6 23.2 44.3 | 15 33 30 49 | 11.8 26.0 23.6 38.6 | 38 119 103 185 | 8.5 26.7 23.1 41.6 | 3 9 12 23 | 6.4 19.1 25.5 48.9 |
Grade | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
I II III | 80 282 203 | 14.2 49.9 35.9 | 45 160 96 | 15.0 53.2 31.9 | 10 43 57 | 9.1 39.1 51.8 | 51 181 134 | 13.9 49.5 36.6 | 13 67 43 | 10.6 54.5 35.0 | 62 219 157 | 14.2 50.0 35.8 | 2 21 23 | 4.3 45.7 50.0 |
Histological type | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Ductal Lobular | 513 53 | 90.6 9.4 | 281 20 | 93.4 6.6 | 102 8 | 92.7 7.3 | 330 37 | 89.9 10.1 | 113 10 | 91.9 8.1 | 396 43 | 90.2 9.8 | 43 3 | 93.5 6.5 |
T-status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
T1 T2 T3/4 | 211 272 72 | 38.0 49.0 13.0 | 113 142 39 | 38.4 48.3 13.3 | 40 54 17 | 36.0 48.6 15.3 | 118 180 60 | 33.0 50.3 16.8 | 57 61 6 | 46.0 49.2 4.8 | 159 209 64 | 36.8 48.4 14.8 | 19 26 2 | 40.4 55.3 4.3 |
N-status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
N0 N1-3 | 307 250 | 55.1 44.9 | 158 135 | 53.9 46.1 | 61 49 | 55.5 44.5 | 193 170 | 53.2 46.8 | 66 55 | 54.5 45.5 | 237 196 | 54.7 45.3 | 24 21 | 53.3 46.7 |
ER-status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Negative Positive | 203 337 | 37.6 62.4 | 113 178 | 38.8 61.2 | 37 73 | 33.6 66.4 | 135 222 | 37.8 62.2 | 43 80 | 35.0 65.0 | 152 278 | 35.3 64.7 | 21 25 | 45.7 54.3 |
PgR-status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Negative Positive | 223 313 | 41.6 58.4 | 130 159 | 45.0 55.0 | 42 68 | 38.2 61.8 | 141 215 | 39.6 60.4 | 51 72 | 41.5 58.5 | 158 267 | 37.2 62.8 | 26 21 | 55.3 44.7 |
Her2-status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Overexpression - Overexpression + | 378 44 | 80.9 19.1 | 207 24 | 89.6 10.4 | 82 10 | 89.1 10.9 | 256 33 | 88.6 11.4 | 93 6 | 93.9 6.1 | 311 32 | 90.7 9.3 | 35 6 | 85.4 14.6 |
Local Therapy | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
MAST-RT MAST+RT BCS-RT BCS+RT | 223 108 5 238 | 38.9 18.8 0.9 41.5 | 116 56 3 130 | 38.0 18.4 1.0 42.6 | 43 24 1 44 | 38.4 21.4 0.9 39.3 | 141 86 1 142 | 38.1 23.2 0.3 38.4 | 46 14 3 64 | 36.2 11.0 2.4 50.4 | 165 94 4 182 | 37.1 21.1 0.9 40.9 | 24 3 0 20 | 51.1 6.4 0.0 42.6 |
Systemic therapy | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
CT alone HT alone CT&HT None | 112 75 18 369 | 19.5 13.1 3.1 64.3 | 65 32 10 198 | 21.3 10.5 3.3 64.9 | 23 10 2 77 | 20.5 8.9 1.8 68.8 | 81 52 13 224 | 21.9 14.1 3.5 60.5 | 20 16 1 90 | 20.3 12.6 0.8 70.9 | 93 60 11 281 | 20.9 13.5 2.5 63.1 | 8 5 1 33 | 17.0 10.6 2.1 70.2 |
Total | 574 | 100 | 305 | 100 | 112 | 100 | 370 | 100 | 127 | 100 | 445 | 100 | 47 | 100 |